Leukemia Research
Volume 29, Issue 6 , Pages 603-604 , June 2005

Trying to improve clinical outcome in AML: Lessons from negative trials

Received 27 December 2004 ,Accepted 27 December 2004.

Reference 

  1. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;199:4325
  2. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312
  3. Hiddeman W, Kern W, Shoch C, Fonatsch C, Heinecke A, Wormann B, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol. 1999;17:3569
  4. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997;89:3323
  5. Estey EH. How I treat older patients with AML. Blood. 2000;96:1670
  6. Sekeres MA, Stone RM, Zahrieh D, Neuberg D, Morriosn V, Se Angelo DJ, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia. 2004;18:809
  7. Du X, Williams DA. Interleukin 11: review of molecular, cell biology and clinical use. Blood. 1997;89:3897
  8. Estey EH, Thall PF, Giles FJ, Wang XM, Cortes JE, Beran M, et al. Gentuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous infusion, high-dose cytosine arabinoside. Blood. 2002;99:4343
  9. Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, et al. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res. 2005;29:649
  10. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. The World Health Organization classification of neoplastic diseases of the hematopoeitic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. Ann Oncol. 1999;10:1419
  11. Estey EH, Thall PF. New designs for phase 2 clinical trials. Blood. 2003;102:442

PII: S0145-2126(05)00048-2

doi: 10.1016/j.leukres.2004.12.013

Leukemia Research
Volume 29, Issue 6 , Pages 603-604 , June 2005

Article Tools